Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 17-18, 2022. The links can also be found at www.sidoticonference.com/events.
| |||
Presentation Agenda | |||
Wednesday, August 17th, 2022 (Day 1) | |||
8:30-9:00 | |||
9:15-9:45 | |||
10:00-10:30 | ***** | ||
10:45-11:15 | |||
11:30-12:00 | |||
12:15-12:45 | |||
1:00-1:30 | |||
1:45-2:15 | |||
2:30-3:00 | ***** | ||
3:15-3:45 | ***** | ||
4:00-4:30 | ***** | ||
1x1s Only | Gulf Island Fabrication (GIFI) | Kelly Services (KELYA) | |
| |||
Thursday, August 18th, 2022 (Day 2) | |||
9:15-9:45 | |||
10:00-10:30 | |||
10:45-11:15 | |||
11:30-12:00 | |||
12:15-12:45 | |||
1:00-1:30 | |||
1x1s Only | American Woodmark (AMWD) | Paysign, Inc. (PAYS | Wireless Telecom Group (WTT) |
About Sidoti
For over two decades, Sidoti has been a premier provider of independent securities research focused specifically on Small Cap and Micro-Cap companies and the institutions that invest their securities, with most of our coverage in the $50 million to $3 billion market cap range. Our approach affords companies and institutional clients a combination of high-quality research, a Small Cap and Micro-Cap focused nationwide sales effort, and broad access to corporate management teams. We serve 500+ institutional clients in the U.S. and Canada, including many leading institutional managers. Sidoti promotes meaningful interaction between issuers and investors in the Small Cap and Micro-Cap space through a series of investor conferences (www.sidoti.com/events) we host each year.
CONTACT
Sidoti Events Team
212-453-7031
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.54 |
| Daily Change: | -0.10 -3.79 |
| Daily Volume: | 25,103 |
| Market Cap: | US$104.340M |
September 29, 2025 May 13, 2025 February 14, 2025 December 23, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
